bioRxivCancer BiologyPreprint
Dynamics of repurposing synthetic and natural compounds against WNT/β-Catenin signaling in glioma- An in vivo approach
D. P. S, S. S. Kuduvalli, I. Biswas, B. K, A. K. B, J. M. Thomas, A. T. S
Abstract
BackgroundGlioblastomas arise from multistep tumorigenesis of the glial cells and are associated with poor prognosis. Despite the current state-of-art treatment, tumor recurrence is inevitable. Thus, there exists a desperate need for effective therapeutic alternatives to improve glioblastoma outcome. Among the innovations blooming up, drug repurposing could provide a profound premises for glioblastoma treatment enhancement. While considering this strategy, the efficacy of the repurposed drugs as monotherapies were not up to par; hence, the focus has now shifted to investigate the multi-drug combinations to target glioblastomas. In line with this concept, we investigated the efficacy of a quadruple-combinatorial treatment comprising temozolomide (the benchmark drug) along with chloroquine (a synthetic drug), naringenin (a flavonoid) and phloroglucinol (a marine derivative) in an orthotopic glioma-induced xenograft model. MethodsAnti-proliferative effect of the drugs was assessed by immunostaining. The expression profiles of WNT/{beta}-catenin and apoptotic markers were evaluated by qRT-PCR, immunoblotting and ELISA. Patterns of mitochondrial depolarization was determined by flow cytometry. TUNEL assay was performed to affirm apoptosis induction. In vivo drug detection study was carried out by ESI-Q-TOF MS analysis. ResultsThe quadruple-drug treatment had significantly hampered GB proliferation and had induced apoptosis by modulating the WNT/{beta}-catenin signalling. Flow cytometric analysis revealed that the induction of apoptosis was associated with mitochondrial depolarization. Further the quadruple-drug cocktail, had breached the blood brain barrier and was detected in the brain tissue and plasma samples from various experimental groups. ConclusionThe quadruple-drug combination served as a promising adjuvant therapy to combat glioma lethality in vivo and can be probed for translation from bench to bedside.
- organism: mouse
- assay: proteomics
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A combination of Metformin and Epigallocatechin Gallate Potentiates Glioma Chemotherapy in vivo
S. S. Kuduvalli, D. P. S, … A. T. S·bioRxiv·Nov 16, 2022
- The synergistic anti-Warburg efficacy of temozolomide, metformin and epigallocatechin gallate in glioblastoma
S. S. Kuduvalli, D. S. Precilla, … A. T. S·Toxicology and Applied PharmacologyPeer-reviewed·Dec 1, 2024
- An anti-depressant drug vortioxetine suppresses malignant glioblastoma cell growth.
M. N. Devare, M. Kaeberlein·bioRxiv·Mar 4, 2024
- Targeting tumour-intrinsic neural vulnerabilities of glioblastoma
S. Lee, T. Weiss, … B. Snijder·bioRxiv·Oct 7, 2022
- Combined Treatment with Dopamine Receptor Antagonists and Radiation Creates a Metabolic Vulnerability in Mouse Models of Glioblastoma
Kruttika Bhat, Mohammad Saki, … Frank Pajonk·JNCI Journal of the National Cancer InstitutePeer-reviewed·Feb 3, 2021
- DIFFERENTIAL ANTIPROLIFERATIVE EFFECTS OF CANNABIDIOL (CBD) IN THE CORE AND INFILTRATIVE BOUNDARY OF HUMAN GLIOBLASTOMA CELLS
Ghazala Abassi-Rana, Yolanda Calle, Francisco Molina‐Holgado·bioRxiv·Sep 17, 2024